[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myopia-progression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myopia-progression":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,46,73,91,113,138,161,188,213,234,258,297,321,350,373],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054152","inhibition-of-myopia-progression-with-optical-devices-100054152",false,"NCT07698977","Inhibition of Myopia Progression With Optical Devices","Inclusion Criteria:\n\n* • Participants must be between 6 and 15 years of age at the start of myopia progression treatment\n\n  * Caucasian ethnicity\n  * Refractive error measured under cycloplegia, expressed as spherical equivalent: between -0.50 Dsph and -10.0 Dsph\n  * Wearing myopia-control glasses while awake\n  * Participation in follow-up examinations every 6 months\n\nExclusion Criteria:\n\n* • Pathological myopia (e.g., myopia onset before age 6, Stickler syndrome)\n\n  * Premature birth before the 32nd week of gestation\n  * Previous eye-opening surgery (e.g., lens removal)\n  * Traumatic eye injury\n  * Known connective tissue disorder (e.g., Marfan syndrome)\n  * Irregular or improper use of progressive-lens glasses\n  * Failure to attend the follow-up examinations scheduled every 6 months","ALL","6 Years","15 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","This observational study aims to determine whether optical devices designed to slow myopia progression and\u002For environmental factors can prevent myopia progression in the pediatric and adolescent myopic population.\n\nThe study aims to answer the following questions:\n\n1. How does myopia progression change with age while wearing myopia progression control glasses?\n2. How does myopia progression change while wearing myopia progression-control glasses when environmental factors, such as time spent outdoors and place of residence, are taken into account?\n3. How does myopia progression change at different ages while wearing myopia progression control glasses given a family history of myopia? This will be a self-controlled observational study. Participants who are myopic after cycloplegic refraction will be prescribed DIMS glasses. DIMS stands for \"defocus incorporated multiple segments,\" a specialized optical technology used in spectacle lenses to slow nearsightedness progression in children.\n\nPatients will keep a diary of their subjective symptoms and environmental factors, e.g., time spent outdoors and screen time.\n\nPatients will visit the clinic once every six months for checkups and the following tests:\n\n* Best corrected visual acuity test\n* Stereopsis\n* Automatic refractometry\n* Bulbar axial length measurement\n\nIn a follow-up study, researchers will compare myopia progression with environmental and baseline factors to learn about the long-term effects of DIMS lenses on myopia progression.",[24,25,26],"Myopia Progression","Myopia","Myopia, Child Myopia Progression",[28,29,30,31,32],"myopia","myopia progression","optical device","DIMS lenses","bulbar axial length","RECRUITING","2026-07-07",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-06-02",{"date":41,"type":20},"2027-05-31",{"name":43,"class":44},"Semmelweis University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100610574","mobility-performance-in-daily-activities-among-children-wearing-spectacle-lenses-100610574","NCT07229352","Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses","Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses","Inclusion Criteria:\n\nA participant is eligible for inclusion in the study if they meet the following criteria:\n\n* Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent\u002Fassent.\n* Can achieve a corrected visual acuity of 20\u002F20 best-corrected (or equivalent logMAR).\n* Have undergone a self-reported oculo-visual examination within the past two years.\n* Have no active ocular disease.\n* Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.\n* Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.\n* The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.\n\nExclusion Criteria:\n\nA participant will be excluded from the study if they meet any of the following conditions:\n\n* Have any systemic disease that affects ocular health.\n* Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.\n* Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.\n* Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.\n* Have known developmental delays.\n* Have participated in another clinical study in the last 7 days",true,"12 Years",{"count":56,"type":20},20,"INTERVENTIONAL",[59],"NA","The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing single vision spectacle lenses (control) versus myopia control spectacle lenses (test).",[25,24,62],"Juvenile Myopia","2026-04-29",{"date":65,"type":37},"2026-04-30",{"date":67,"type":37},"2026-02-02",{"date":69,"type":20},"2027-07-01",{"name":71,"class":72},"SightGlass Vision, Inc.","INDUSTRY",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":53,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":90,"locationsCount":45},"100610575","childrens-viewing-behavior-100610575","NCT07229365","Children's Viewing Behavior","Children's Viewing Behavior in Myopia Control Spectacles","Inclusion Criteria:\n\nA person is eligible for inclusion in the study if he\u002Fshe:\n\n* Is 7-14 years of age, inclusive\n* Requires spherical spectacle lenses within the power range available for the study lenses\n* Parent\u002Fguardian has read and understood the informed consent form, and the child has provided age-appropriate assent\n* Is willing and able to follow instructions and maintain the appointment schedule\n* Is correctable to a visual acuity of 20\u002F40 or better (in each eye) with their habitual vision correction or 20\u002F20 best corrected\n* Has had a self-reported oculo-visual examination in the last two years\n* Spectacle cylinder of ≤ -0.75DC in both eyes\n\nExclusion Criteria:\n\nA person will be excluded from the study if he\u002Fshe:\n\n* Is unable to complete the necessary study activities\n* Has any systemic disease affecting ocular health\n* Is using any systemic or topical medications (including pharmaceutical myopia control therapy) that will affect ocular health\n* Is aphakic","7 Years","14 Years",{"count":56,"type":20},[59],"The aim of this study is to investigate the area of the spectacle lens in which a subject is viewing through regardless of task being performed.",[25,24,62],{"date":65,"type":37},{"date":88,"type":37},"2025-12-22",{"date":69,"type":20},{"name":71,"class":72},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":81,"enrollmentInfo":99,"targetDuration":4,"studyType":57,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":45},"100628535","evaluation-of-the-effectiveness-of-a-new-generation-of-myopia-control-lens-on-the-progression-of-myopia-in-children-aged-6-to-14-years-100628535","NCT07462897","Evaluation of the Effectiveness of a New Generation of Myopia Control Lens on the Progression of Myopia in Children Aged 6 to 14 Years","Evaluation of the Effectiveness of a New Generation of Myopia Control Lens, Producing a Higher Myopic Control Signal Than That Produced by a Previous Generation Lens, on the Progression of Myopia in Children Aged 6 to 14 Years","VERCORS","Inclusion Criteria:\n\n* Refractive error in spherical equivalent (SE) ≤ -0.5 D and ≥ -4.5 D on each eye (autorefraction under cycloplegia)\n* Astigmatism ≤ 2.00 D for each eye\n* Anisometropia (difference in SE between the 2 eyes) ≤ 1.00 D\n* Corrected maximum distance visual acuity in each eye≥ 8\u002F10 (equivalent to +0.1 LogMAR)\n* Written consent of the 2 holders of parental authority (or only one in the case of exclusive parental authority) and agreement of the participant\n\nExclusion Criteria:\n\n* Past or current use of any type of myopic control solution (braking lenses, atropine, orthokeratology, multifocal contact lenses, etc\n* Strabismus (in the test of masking near or far with the best correction)\n* Amblyopia\n* Any ocular or systemic condition known to affect refractive status (e.g., keratoconus, diabetes, Down syndrome, etc.)\n* Presence of trauma in at least one eye - Presence of inflammatory pathologies in at least one eye\n* History of intraocular surgery (cataracts, filtering surgery, intravitreal surgery) in at least one eye\n* Past or current use of growth hormones\n* Use of ocular or systemic drugs that, in the opinion of the investigator, may significantly affect pupil size, accommodation, or refractive status.\n* Wearing contact lenses\n* Allergy or intolerance to cycloplegic eye drops (cyclopentolate 0.5%)\n* Known allergy or intolerance to eyeglass frame materials\n* Children with specific visual disorders requiring personalized treatments other than conventional corrective lenses.\n* Intolerance to conventional optical corrections\n* Lack of cooperation in wearing corrective lenses",{"count":100,"type":20},76,[59],"The goal of this clinical investigation is to learn how much a new generation of myopia control lens (MCL1 - Myopia Control Lens 1) is helpful in reducing myopia progression in children from 6 to 14 yo. The main questions it aims to answer is: How much this new generation of lens, called MCL1, slows down the growth of the eye? Researchers will compare MCL1 to a former generation of myopia control lens (i.e. MCL2) but with better vision quality.\n\nParticipants will:\n\n* Wear MCL1 on right eye and MCL2 on left eye for 6 months and MCL2 on rigth eye and MCL1 on left eye for the next 6 months;\n* Visit the hospital at 6 and 12 months for tests;\n* Answer weekly questionnaires on compliance wearing glasses, quality of vision and out-of-school activities.",[24],"2026-04-20",{"date":106,"type":37},"2026-04-23",{"date":108,"type":37},"2026-03-18",{"date":110,"type":20},"2028-05",{"name":112,"class":72},"Essilor International",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":57,"phases":122,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":45},"100634135","phase-3-the-effect-of-myopia-control-contact-lenses-in-new-zealand-chinese-children-100634135","NCT07535749","The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children","Inclusion Criteria:\n\n* Spherical refractive error between -1.00D and -4.50D\n* Astigmatism of ≤1.00D\n* No history of orthokeratology or atropine use\n* No ocular diseases or surgical history\n\nExclusion Criteria:\n\no No ocular diseases or surgical history","11 Years",{"count":121,"type":20},66,[123],"PHASE3","The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children.\n\nThe study duration will be 6 months, with assessments conducted at baseline, 2 weeks, 3 months, and 6 months.\n\nThe clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.",[24],[127,128],"myopia control","contact lenses","2026-04-10",{"date":131,"type":37},"2026-04-17",{"date":133,"type":37},"2026-03-21",{"date":135,"type":20},"2026-12-30",{"name":137,"class":44},"Aston University",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":145,"targetDuration":147,"studyType":21,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100623278","prospective-research-on-the-intervention-of-myoless20-effectiveness-prime-in-pediatric-population-100623278","NCT07394556","Prospective Research on the Intervention of Myoless2.0 Effectiveness (PRIME) in Pediatric Population","PRIME","Inclusion Criteria:\n\n* Be aged between 6 to 12 completed years (6 and 12 years inclusive), irrespective of gender.\n* For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old.\n* Be cycloplegic autorefraction spherical component -0.50 D to -6.00D, cylinder no more than -2.00D, and with a spherical equivalent greater than or equal to -6.00D.\n* Be accompanied by parents\u002Fguardians who can read and comprehend give informed consent as demonstrated by signing a record of informed consent.\n* Be willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.\n* Have ocular health findings considered to be \"normal\".\n* Be correctable to at least 6\u002F9.5 (20\u002F30) or better in each eye with spectacles.\n* Be willing to wear the spectacles provided by the investigators for all waking hours.\n\nExclusion Criteria:\n\n* A known allergy to, or a history of intolerance to cyclopentolate or topical anesthetics.\n* Had strabismus and\u002For amblyopia.\n* Cylinder more than -2.00D\n* Anisometropia greater than 1.50D spherical equivalent\n* Had previous eye surgery (including strabismus surgery).\n* Any ocular, systemic or other condition or disease with possible associations with myopia or affecting refractive development e.g. Marfan syndrome, retinopathy of prematurity, diabetes.\n* Had any ocular injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids.\n* Current orthoptic treatment or vision training.\n* Any anatomical, skin or other condition that would impact on the wearing of spectacles.\n* Use of or need for concurrent category S3 and above ocular medication at enrolment and\u002For during the clinical trial.\n* Currently enrolled in another clinical trial.\n* No previous myopia management intervention or treatment.",{"count":146,"type":20},180,"24 Months","The Goal of the study is to evaluate the rate of myopia progression with open ring myopia control spectacle lens designs compared to a commercial peripheral plus myopia control spectacle lens (CML) in European children with myopia. This is a prospective, randomized, bilateral wear, double masked, cross-over clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML).\n\nGroup 2 - 60 participants will wear the Open Ring 1 (OR1) lens design. Group 3 - 60 participants will wear the Open Ring 2 (OR2) lens design. For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old. All groups will be required to wear spectacles for all waking hours for 12 months. After 12 months, the control group will continue wearing CML for a further 12 months; the Group 2 participants will continue wearing the OR1 lens for a further 12 months. The Group 3 participants will wear OR2 or OR3 (a modified design of OR2) based on their risk of myopia progression for a further 12 months",[24],"NOT_YET_RECRUITING","2026-03-03",{"date":153,"type":37},"2026-03-05",{"date":155,"type":20},"2026-04",{"date":157,"type":20},"2028-10",{"name":159,"class":72},"Indizen Optical Technologies, S.L.U.",3,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":15,"minAge":168,"maxAge":80,"enrollmentInfo":169,"targetDuration":4,"studyType":57,"phases":170,"briefSummary":171,"conditions":172,"keywords":175,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":45},"100620957","myopia-progression-control-using-atropine-005-after-pediatric-cataract-surgery-and-intraocular-lens-implantation-surgery-100620957","NCT07364370","Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery","Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery: A Randomized Clinical Trial","Inclusion criteria:\n\n1. Children after IOL implantation (primary or secondary)\n2. Age 1-7 years\n\nExclusion criteria:\n\n1. Eyes with post-operative media opacity hindering adequate assessment of refraction\n2. Eyes with complicated surgeries (e.g. vitreous loss, dropped lens matter requiring PPV, retinal detachment, etc)\n3. Retinal pathologies\n4. Glaucoma (congenital or secondary to surgery)\n5. Anterior or posterior segment anomalies","1 Year",{"count":19,"type":20},[59],"Myopic shift remains a debilitating and unpredictable adverse event following pediatric cataract surgery. While research exploring peripheral myopic defocus for post-cataract surgery myopia prevention shows promising results, the use of multifocal intra-ocular lenses (IOLs) cannot be used liberally in countries with high disease burden and challenged economies due to high price and decreased availability. To date there are no studies evaluating the use of topical atropine for the management of myopic shift following pediatric cataract surgery.\n\nThe investigators aim to explore the use of 0.05% topical atropine in the prevention and management of myopic shift following pediatric cataract surgery.",[173,174,24],"Pediatric Cataract","IOL Implantation",[176,177,178,28],"pediatric cataract","iol","iol implantation","2026-01-15",{"date":181,"type":37},"2026-01-23",{"date":183,"type":20},"2026-02",{"date":185,"type":20},"2027-12",{"name":187,"class":44},"Cairo University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":15,"minAge":196,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":57,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100618296","phase-3-atropine-in-the-treatment-of-myopia-study-in-malaysia-100618296","NCT07329777","Atropine in the Treatment of Myopia Study in Malaysia","Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY): A Randomized, Double-Blind Study to Demonstrate the Efficacy and Safety of Eye Drop Formulations (Atropine Sulphate 0.025 % w\u002Fv Eye Drops vs Placebo) in the Management of Controlling Progression of Myopia in Children.","ATOM-MY","Inclusion Criteria:\n\n1. Male or female children between 5 to 10 years of age.\n2. Children with refractive error of spherical equivalent -1.00 D up to -6.00 D in each eye.\n3. Children with active myopia progression of at least spherical equivalent -0.50 D within the last 12 months.\n4. Children with astigmatism of less than -1.50 D\n5. Children having distance vision correctable to logMAR 0.2 or better in both eyes.\n6. A difference between non-cycloplegic subjective spherical refraction and cycloplegic subjective spherical refraction of not greater than -1.00 D.\n7. Children with normal intraocular pressure of not greater than 21 mmHg in either eye.\n8. Children with normal ocular health other than myopia.\n9. Children must be in good general health with no history of cardiac or respiratory diseases as per investigator's discretion and does not affect the study treatment or subsequent follow-ups.\n10. No asthma-requiring medications in the past one year.\n11. No known allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride.\n12. Willing and able to comply with scheduled visits and other study procedures.\n13. Written Informed Consent from parent and assent from child has been obtained.\n\nExclusion Criteria:\n\n1. History of hypersensitivity or allergy to study drug and\u002For any of the study medication ingredients.\n2. Children with prior and\u002For concomitant use of other myopia control drugs, contact lens or spectacles (except normal spectacles including tinted\u002Fanti-glare glasses) etc.\n3. Children with congenital myopia.\n4. Children using Ortho K and Myopia Lens.\n5. Children with ocular or systemic diseases which may affect vision or refractive error.\n6. Children with any ocular condition wherein topical atropine is contraindicated.\n7. Children with defective binocular function or stereopsis.\n8. Children with amblyopia (lazy eyes) or manifest strabismus including intermittent tropia.\n9. Previous or current use of atropine or pirenzepine.\n10. Children with any other conditions precluding adherence to the protocol including unwillingness to refrain from the use of other myopia control drug, contact lens or spectacles (except normal) spectacles including tinted\u002Fanti-glare glasses) etc. for the duration of the study.\n11. Children with any other condition which may put the subject to risk during study or affect study results based on investigator's judgement.\n12. Children participated in any clinical study within 30 days prior to randomization.","5 Years","10 Years",{"count":199,"type":20},144,[123],"This clinical trial is designed to assess the efficacy and safety of Atropine Sulphate 0.025% w\u002Fv Eye Drops compared to placebo in a randomized, double-blind, placebo-controlled study for the management of myopia progression in children.",[24],"2025-12-29",{"date":205,"type":37},"2026-01-09",{"date":207,"type":37},"2025-09-17",{"date":209,"type":20},"2029-09",{"name":211,"class":72},"IDB VisionCare SDN BHD",2,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":57,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},"100518729","efficacy-in-controlling-myopia-in-young-children-using-a-novel-spectacle-lens-100518729","NCT06034327","Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens","EUCALYPTUS","Inclusion Criteria:\n\n1. Children 6 - 8 years of age (inclusive) at time of informed consent\u002Fassent;\n2. Spherical equivalent refractive error between -0.75 and -4.50 D inclusive (by manifest refraction) in each eye;\n3. Astigmatism if present, less than or equal to -1.25 DC (by manifest refraction) in each eye;\n4. Best corrected visual acuity by manifest refraction of +0.10 logMAR (20\u002F25 Snellen equivalent) or better in each eye;\n5. The difference in spherical equivalent power between the two eyes (anisometropia based on manifest refraction) must be less than or equal to 1.50 D;\n6. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day);\n7. Ability to comply with study procedures, including high and low contrast visual acuity, axial length, and cycloplegic autorefraction measurements taken for both eyes at the baseline visit;\n8. Willingness to participate in the trial for 24 months without contact lens wear;\n9. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form.\n\nExclusion Criteria:\n\n1. Subject has previously or currently wears contact lenses (greater than 1-month usage);\n2. Current or prior use of bifocals, progressive addition spectacle lenses\n3. Current or prior use of any myopia control treatment (e.g., atropine, multifocal contact lenses, orthokeratology);\n4. Amblyopia in either eye;\n5. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction;\n6. Any ocular or systemic conditions that could influence refractive development or status \\[e.g., keratoconus, congenital glaucoma, ocular trauma, diabetes, Marfan syndrome or other connective tissue disorder, Down's syndrome, family history of poor night vision (to prevent against enrolling subjects with congenital stationary night blindness)\\];\n7. Known allergy to proparacaine, tetracaine, or tropicamide;\n8. Participation in any investigational clinical study within 30 days of the Baseline visit;\n9. Subject's sibling or other household member is already enrolled in this trial.","8 Years",{"count":222,"type":20},150,[59],"This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy.\n\nThis is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.",[25,62,24],"2025-12-24",{"date":203,"type":37},{"date":229,"type":37},"2023-09-18",{"date":231,"type":20},"2027-03-31",{"name":71,"class":72},14,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":17,"enrollmentInfo":241,"targetDuration":4,"studyType":57,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":212},"100583576","the-arrest-contact-lens-study-100583576","NCT06878118","The A.R.R.E.S.T.® Contact Lens Study","Prospective, Controlled, Randomised, Contralateral Wear, Dispensing Trial to Assess the Efficacy of Contact Lenses Using A.R.R.E.S.T.® Technology","Inclusion Criteria\n\n* Be between 7 to 15 years old inclusive at time of enrolment.\n* Have:\n\n  * Read the Informed Assent.\n  * Been explained the Informed Assent.\n  * Indicated an understanding of the Informed Assent.\n  * Signed the Informed Assent.\n* Have their parent \u002F legal guardian.\n\n  * Read the Informed Consent.\n  * Been explained the Informed Consent.\n  * Indicated an understanding of the Informed Consent.\n  * Signed the Informed Consent.\n* Along with their parent\u002Flegal guardian, be capable of comprehending the nature of the study and be willing to adhere to the study requirements.\n* Along with their parent\u002Flegal guardian, agree to maintain the visit and prescribed wearing schedule.\n* Agree to wear the study contact lenses for a minimum of 5 days\u002Fweek, 6 hours\u002Fday on days lenses are worn but not \\> 16 hours per day, and to remove lenses at night (i.e., daily wear only with no contact lens wear during sleep), for the duration of the study and to inform the investigator if their schedule is interrupted. Wearing time can be modified by the investigator for health reasons.\n* Be in good general health, based on parent's\u002Flegal guardian's knowledge.\n* Have best-corrected high contrast visual acuity of 0.10 logMAR (Snellen: 20\u002F25, 6\u002F7.6; Decimal: 0.80) or better in each eye.\n* Meet the following criteria determined by cycloplegic autorefraction at Baseline:\n\n  * -4.00 D ≤ spherical equivalent ≤ 0.75 D\n  * -1.00 DC ≤ astigmatic component ≤ 0 DC\n* Participants who fail astigmatism criterion with autorefraction pass astigmatism criterion if ≥ 0.75 D is measured with subjective refraction.\n\n  * \\|Spherical equivalent anisometropia\\| ≤ 1.00 D.\n\nExclusion Criteria\n\n* Participant in another study within 30 days prior to this study.\n* Current or prior use of interventions intended for myopia control, including but not limited to:\n* Optical devices:\n\n  * Bifocal \u002F multifocal spectacles.\n  * Bifocal \u002F multifocal contact lenses.\n  * Orthokeratology.\n* Pharmacological agents:\n\n  * Atropine with a concentration \\> 0.01%.\n  * Participants who have previously used 0.01% atropine are eligible for this study provided they agree not to use 0.01% atropine for at least 30 days before baseline and at any time during the study.\n  * Pirenzepine.\n* Participant born earlier than 30 weeks or weighed \\\u003C 1500 g at birth.\n\n  o A verbal report from the participant's parent \u002F legal guardian is sufficient.\n* Habitual use of a systemic or topical medication that may alter normal ocular findings \u002F is known to affect a participant's ocular health \u002F physiology either in an adverse or beneficial manner at enrolment and \u002F or during the clinical trial.\n* A known allergy to sodium fluorescein, benoxinate, proparacaine, tropicamide, or cyclopentolate.\n* A known corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections, or any other recurrent ocular infections.\n* Strabismus as determined by cover test at distance (≥ 3 m) or near (40 cm) while wearing distance correction under non-cycloplegic conditions.\n* Known ocular or systemic disease, such as but not limited to:\n\n  * Diabetes.\n  * Graves' disease.\n  * Glaucoma.\n  * Uveitis.\n  * Scleritis.\n  * Auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome, and systemic lupus erythematosus.\n  * Any ocular, systemic, or neuro-developmental conditions that could influence refractive development, such as but not limited to:\n  * Persistent pupillary membrane.\n  * Vitreous haemorrhage.\n  * Cataract.\n  * Central corneal scarring.\n  * Eyelid haemangiomas.\n  * Marfan's syndrome.\n  * Down's syndrome.\n  * Ehler's-Danlos syndrome.\n  * Stickler's syndrome.\n  * Ocular albinism.\n  * Retinopathy of prematurity.\n  * Keratoconus or irregular cornea.\n* Biomicroscopic that contraindicate contact lens, such as but not limited to:\n\n  * Neovascularisation or ghost vessels ≥ 1.5 mm in from limbus.\n  * Any active anterior segment disease that contraindicates safe contact lens wear.\n  * Clinically significant giant papillary conjunctivitis.\n  * Clinically significant abnormalities of the anterior segment, lids, conjunctiva, sclera, or associated structures.\n  * Allergic or seasonal conjunctivitis if the investigator believes it could significantly interfere with maintaining a specified wearing schedule.\n* The investigator may, at their discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests.",{"count":242,"type":20},80,[59],"The goal of this clinical trial is to learn if contact lenses using Active Reconfiguration in Retinal Encoding of Spatio-Temporal (A.R.R.E.S.T.®) signal technology works to slow down the rate of myopia progression compared to single vision contact lenses in myopic children. The main questions it aims to answer are:\n\nDo contact lenses using A.R.R.E.S.T.® technology slow down the rate of axial length growth? Do contact lenses using A.R.R.E.S.T.® technology slow down the rate of increase in myopic refractive error?\n\nResearchers will compare contact lenses using A.R.R.E.S.T.® technology to a single vision contact lens.\n\nParticipants will:\n\nBe randomly allocated to wear either contact lenses using A.R.R.E.S.T.® technology or single vision contact lenses.\n\nVisit the clinic on seven occasions over a 12 month period.",[25,24],[247],"axial length","2025-09-29",{"date":250,"type":37},"2025-10-03",{"date":252,"type":37},"2025-07-06",{"date":254,"type":20},"2026-11-01",{"name":256,"class":257},"nthalmic Pty Ltd","NETWORK",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":53,"sex":15,"minAge":80,"maxAge":197,"enrollmentInfo":265,"targetDuration":4,"studyType":57,"phases":267,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":296},"100564604","optimizing-light-exposure-for-myopia-prevention-and-control-lightspan-100564604","NCT06631339","Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)","LightSPAN","Inclusion Criteria:\n\n* Subject must meet all the inclusion criteria below to participate in this study.\n\n  1. Written Informed Consent form from parent \u002F legal guardian and assent from child subject has been obtained\n  2. Is between 7 to 10 years of age at start of study intervention which is 2 January 2025 or 1 January 2026\n  3. Studying in either Primary 2 or 3 classes of the participating school(s) in academic year 2025 or 2026.\n  4. Presenting visual acuity or best corrected visual acuity (BCVA) better or equal to LogMAR 0.2 (equivalent to Snellen 6\u002F9 or better) in each eye\n  5. Normal Intraocular pressure (not more than 21mmHg)\n  6. No ocular conditions (e.g., optic nerve disease, glaucoma, retinal diseases) except for refractive error.\n  7. No ocular conditions affecting the accuracy of the ophthalmic examinations\n  8. In good general health with no significant systemic diseases that may affect eye health\n\n     Exclusion Criteria:\n* All subjects meeting any of the exclusion criteria at baseline will be excluded from participation.\n\n  1. Previous or ongoing myopia control treatment (including but not limited to orthokeratology, atropine, pirenzepine, myopia control spectacle and contact lenses, light therapy)\n  2. Ongoing participation in other myopia prevention and control research trials\n  3. Any systemic or neurologic diseases (e.g. cancer, epilepsy, Kawasaki disease) known to affect eye health or make the participant vulnerable to the ophthalmic examinations (e.g., light flash)\n  4. Any other conditions precluding adherence to the protocol including unwillingness to refrain from myopia control treatment for the duration of the study",{"count":266,"type":20},396,[59],"The goal of this clinical trial is to evaluate whether the optimization of daily exposure to light in primary school children can lead to better myopia prevention and control. The trial also aims to better understand the impact of light exposure on sleep and cognitive performance in children.\n\nThis trial has 3 arms namely, (1) a technical intervention arm, (2) a digital intervention arm, and (3) a control arm.\n\n1. technical intervention - which involves changing of classroom lighting in primary schools to ceiling lights that mimic the spectral composition of sunlight and fluctuates in intensity. Parents of children within that arm will have a sham smart-phone application (s-LightUP)\n2. digital intervention - which involves standard classroom lighting and giving parents an interventional smart-phone application (i-LightUP) that will be coupled with their child's light and activity sensor (wrist worn device ). The interventional app will provide individually tailored recommendation based on their children's behaviour (data feedback that is collected from the light and activity monitoring watch). The interventional app would then send reminder prompts\u002Fnotifications to encourage parents help their children achieve required amounts of myopia-preventive light quantum target set per day.\n3. Standard care or control group which involves standard classroom lighting and parents having a sham smart-phone application (s-LightUP)\n\nParticipants will:\n\n* be randomised to receive either no intervention (control group), technical intervention (light intervention that mimics sunlight) or digital intervention (parents having an app that syncs with child's light and activity sensor which will provide feedback to parents to encourage and recommends increment of outdoor activities and hours).\n* have their myopia progression monitored every 6 monthly and cognitive assessment done once every 3 months over a year.\n* wear the light and activity sensor watches throughout the 1-year study period as much as possible (minimum 1 week per month) except for wet water activities such as swimming, diving and showering for research data collection purpose.",[25,270,24,271,272],"Light; Therapy, Complications","Short-Sighted","Myopia; Refractive Error",[274,275,25,276,277,278,279,280,281,282,283,284,285,286],"Light Exposure","Digital Intervention","Myopia Prevention","Cognition","Light Intervention","Behaviour changing phone application","Classroom","School-based","School","Singapore","Primary School","Light therapy","Myopia-control","2025-09-21",{"date":289,"type":37},"2025-09-23",{"date":291,"type":37},"2024-10-21",{"date":293,"type":20},"2027-01-26",{"name":295,"class":44},"National University of Singapore",5,{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":304,"targetDuration":4,"studyType":57,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":320},"100570508","phase-3-the-effectiveness-and-safety-of-two-low-concentration-atropine-sulfate-eye-drops-001002-for-delaying-the-pediatric-myopia-progression-100570508","NCT06708156","The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%\u002F0.02%) for Delaying the Pediatric Myopia Progression","The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%\u002F0.02%) for Delaying the Progression of Myopia in Children and Adolescents in a Randomized, Double-blind, Placebo Parallel-controlled, Multicenter, Phase III Clinical Trial","Inclusion Criteria:\n\n1. The legal guardian of the subject voluntarily signed the written informed consent, and the subject over 8 years is required to sign the written informed consent voluntarily.\n2. Patients with myopia aged 6 to 12 years, including cut-offs.\n3. The equivalent spherical refraction ranges from -1.00 D to -4.00 D (automatic optometry under a cycloplegia condition) in both myopia eyes at inclusion screening.\n4. The astigmatism of both eyes was ≤ 1.50 D under a cycloplegia condition at inclusion screening.\n5. The antimetropia (measured by equivalent spherical refraction) is \\\u003C 2.00 D at inclusion screening.\n6. Able to comply with study requirements, attend all study visits (including telephone visits), and be willing to receive random grouping of atropine treatment or placebo.\n\nExclusion Criteria:\n\n1. Allergic to this product or its excipients.\n2. Suffering from eye diseases that may affect vision (e.g. lens diseases such as cataracts, glaucoma, fundus macular disease, keratopathy, uveitis, retinal detachment, severe vitreous opacity, etc., manifest strabismus, nystagmus, ocular acute inflammatory disease), history of recurrent chronic ocular inflammation, or any other ocular pathology (e.g., angular stenosis, shallow anterior chamber).\n3. Intraocular pressure of either eye is \\> 21 mmHg or \\\u003C10 mmHg at screening.\n4. Use of low-concentration (0.05% and below) atropine sulfate eye drops (including various in-hospital preparations, except for test drugs) and orthokeratology lenses (OK lenses) within 6 months before the screening.\n5. Use of other myopia control methods such as instruments (multifocal glasses, progressive multifocal glasses, etc.), medications (the use of cycloplegic agents for examinations such as optometry is allowed), and others (including traditional Chinese medicine, auricular acupuncture, massage, accommodative flippers, red light therapy instrument, etc.) within 3 months before screening.\n6. Those who have participated in other clinical trials and received drug or medical device interventions within 3 months before screening.\n7. Systemic or topical use of drugs that affect the efficacy evaluation, such as anticholinergics: atropine, pirenzepine, etc., and cholinomimetics: pilocarpine, etc. within 1 week before screening.\n8. Combined with severe immune system disease, central nervous system disease, Down syndrome, asthma, cardiopulmonary insufficiency, liver and kidney dysfunction, etc.\n9. Surgical intervention (ocular or systemic) within 6 months before screening, or planned surgery during the study.\n10. Heart rate sustained (more than 10 minutes) greater than 120 beats\u002Fmin at screening (after 10 minutes of rest if the ECG shows a heart rate greater than 120 beats per minute, the ECG should be retested 10 minutes later. If the retest result below 120 beats\u002Fmin, the screening is successful; If the retest result is still \\>120 beats\u002Fmin, screening failed).\n11. Need for ocular use or systemic oral corticosteroids during the study. Intranasal, inhaled, topical cutaneous, intra-articular, perianal steroids, and short-term oral steroids (i.e., continuous use for \\\u003C 2 weeks).\n12. Other conditions that are considered unsuitable by the investigator.",{"count":305,"type":20},606,[123],"The clinical trial aims to test the effectiveness and safety of two low-dose atropine sulfate eye drops for delaying myopia progression in children and adolescents.\n\nPrimary Objective: evaluate the effectiveness of 0.01% and 0.02% atropine sulfate eye drops for 96 weeks compared to placebo in delaying myopia progression in children and adolescents. Secondary Objective: evaluate the safety of two low-concentration atropine sulfate eye drops (0.01%\u002F0.02%) in delaying myopia progression in children and adolescents.\n\nExploratory Objective:\n\n1. the efficacy and safety of two low-concentration atropine sulfate eye drops (0.01%\u002F0.02%) for 144 weeks.\n2. evaluate the rebound effect of two low-concentration atropine sulfate eye drops (0.01%\u002F0.02%) after discontinuation.",[25,24],[25,310],"Atropine","2024-12-19",{"date":313,"type":37},"2024-12-24",{"date":315,"type":37},"2024-06-15",{"date":317,"type":20},"2027-12-31",{"name":319,"class":44},"Oupushifang Pharmaceutical Technology Co., Ltd.",25,{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":329,"targetDuration":4,"studyType":57,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":45},"100571191","evaluation-of-performance-of-miyosmart-photochromic-and-clear-spectacle-lenses-in-myopic-children-100571191","NCT06717035","Evaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children","Evaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children.","PDIMS","Inclusion Criteria\n\nSubjects must meet all the criteria listed to participate in the study:\n\n1. All ethnicities\n2. Age between 6 and 15 years\n3. Refraction -0.50D till - 7.00D and astigmatism ≤ 3.00D\n4. Anisometropia ≤ 3.00D\n5. Best corrected monocular distance high contrast VA ≤ 0.10 logMAR\n6. Normal Binocular vision (fusion and stereopsis)\n\nExclusion Criteria\n\nAll subjects meeting any of the exclusion criteria at baseline will be excluded from participation:\n\n1. Ocular and systemic abnormalities\n2. Children who do not cooperate\n3. Binocular vision anomalies (strabismus, suppression)\n4. Previous use of myopia management treatment (spectacles, atropine, CLs)\n5. Neurological disorders\n6. Premature infants\n7. Children who do not wear their glasses correctly for intermediate and near vision activities\n8. Children who do not meet the inclusion criteria\n9. No informed consent given by parents of child for participation in the clinical study\n10. Subject is allergic to cycloplegic eye drops",{"count":330,"type":20},202,[59],"This clinical study aims to evaluate the non-inferiority of the photochromic DIMS spectacles lenses performance (PDIMS) compared to clear DIMS spectacles lenses (DIMS) in myopia management.",[25,24],[25,335,336,337,338,339],"Spectacles","Glasses","Myopia Control","Pediatric","DIMS","2024-11-29",{"date":342,"type":37},"2024-12-04",{"date":344,"type":20},"2025-01-02",{"date":346,"type":20},"2027-01-02",{"name":348,"class":349},"Singapore National Eye Centre","OTHER_GOV",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":57,"phases":360,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":4},"100564022","study-on-the-impact-of-desk-and-chair-adaptation-intervention-on-the-occurrence-and-development-of-myopia-in-primary-school-students-100564022","NCT06623760","Study on the Impact of Desk and Chair Adaptation Intervention on the Occurrence and Development of Myopia in Primary School Students","Intervention Study：Study on the Impact of Desk and Chair Adaptation Intervention on the Occurrence and Development of Myopia in Primary School Students","Inclusion Criteria:\n\n* Students and their families were informed and voluntarily participated in the study, with parents signing the informed consent form.\n* Able to cooperate with eye examinations and questionnaires.\n\nExclusion Criteria:\n\n* Communication barriers, unable to cooperate.\n* Strabismus, amblyopia, or any other ocular or systemic diseases that may affect refractive development.\n* Children currently using orthokeratology lenses or rigid contact lenses.\n* Using other interventions (such as acupuncture, massage, medication, ear acupuncture, etc.) to control myopia, apart from school eye exercises.","13 Years",{"count":359,"type":20},2100,[59],"This study is a randomized controlled trial of a desk and chair adaptation intervention involving primary school students and their parents or primary caregivers. We compared the myopia status of students in the intervention and control groups before and after the intervention to confirm the effect of the desk and chair adaptation intervention on the development of myopia in students.",[363,25,24],"Axial Length, Eye","2024-09-30",{"date":366,"type":37},"2024-10-02",{"date":368,"type":20},"2024-10-01",{"date":370,"type":20},"2025-12-30",{"name":372,"class":44},"Fangbiao Tao",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":53,"sex":15,"minAge":16,"maxAge":380,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":45},"100554427","factors-influencing-physiological-hyperopia-in-children-100554427","NCT06498947","Factors Influencing Physiological Hyperopia in Children","Factors Influencing Physiological Hyperopia in Children: A Prospective Nested Case-control Study","Inclusion Criteria:\n\n1. Children aged 6-9 years old, male or female;\n2. Good cooperation in examination;\n3. Parents cooperate and sign the informed consent form;\n\nExclusion Criteria:\n\n1. Children with a history of drug allergy;\n2. Pediatric patients with heart disease, cranial trauma or epilepsy, Down syndrome, or glaucoma will be excluded from the cohort.","9 Years",{"count":382,"type":20},1006,"The trend of myopia in children and its low age is a major social and public health problem in China. More seriously, retinopathy associated with high myopia has become the number one cause of irreversible blinding eye disease in adults in some parts of China. Physiological hyperopia has a protective effect on preventing the onset of myopia, and is one of the strongest predictors of myopia on its own, which is significant in curbing myopia from occurring at a younger age and preventing the development of high myopia before adulthood. However, it is not yet known how the physiological hyperopia changes in childhood, the stage at which the critical inflection point occurs, which key factors lead to the rapid fading of the physiological hyperopia and progression to myopia, and the strength of its effect. In the early stage of the study, the research group established a prospective cohort of preschoolers based on natural population sampling, which included a total of 2109 preschoolers aged 3-6 years from 22 kindergartens in a district in Beijing, and completed a 2-year follow-up, obtaining exploratory results on the changing pattern of physiological hyperopia and key influencing factors in younger children. The group will add new samples to the existing whole cohort sampling cohort and adopt the design scheme of prospective nested case-control study to determine the changing trend of fading trajectory of physiological hyperopia in school-age children, key inflection points and key risk factors, so as to provide new techniques for the prevention and control of childhood myopia.",[24],"2024-07-05",{"date":387,"type":37},"2024-07-12",{"date":389,"type":37},"2024-06-01",{"date":391,"type":20},"2026-12-31",{"name":393,"class":44},"Beijing Tongren Hospital"]